The current stock price of GCTK is 3.91 USD. In the past month the price decreased by -17.51%. In the past year, price decreased by -96.66%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.19 | 209.93B | ||
| ISRG | INTUITIVE SURGICAL INC | 60.82 | 185.65B | ||
| SYK | STRYKER CORP | 27.56 | 138.80B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.09 | 135.95B | ||
| BDX | BECTON DICKINSON AND CO | 14.3 | 58.85B | ||
| IDXX | IDEXX LABORATORIES INC | 55.23 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.13 | 49.41B | ||
| RMD | RESMED INC | 26.19 | 37.85B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.67 | 36.94B | ||
| DXCM | DEXCOM INC | 38.77 | 28.12B | ||
| PODD | INSULET CORP | 62.35 | 20.05B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.7 | 17.15B |
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
GLUCOTRACK INC
301 Rt 17 North, Suite 800
Rutherford NEW JERSEY US
Employees: 11
Phone: 197286757878
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
The current stock price of GCTK is 3.91 USD. The price increased by 2.89% in the last trading session.
GCTK does not pay a dividend.
GCTK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
GLUCOTRACK INC (GCTK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
GLUCOTRACK INC (GCTK) currently has 11 employees.